Avidity Biosciences (RNA) said Tuesday it has received orphan drug designation from Japan's Ministry of Health, Labor and Welfare for delpacibart etedesiran, or del-desiran, to potentially treat myotonic dystrophy type 1, a neuromuscular disease.
The investigational drug has also received breakthrough therapy, orphan drug and fast track designations by the US Food and Drug Administration, and orphan designation by the European Medicines Agency, Avidity said.
The company said it expects to complete enrollment in a phase 3 trial in the middle of this year and file marketing applications starting 2026 in the US, European Union and Japan.
Avidity shares were rising more than 2% in early trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.